Q3 FY2026 · ended Sep 30, 2026 · Revenue $42,000, +162.5% YoY · Filed Nov 4, 2026
Sera Prognostics, Inc. (SERA) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $42,000 and a net loss of $8.1 million. Free cash flow was -$7.4 million. As of Sep 30, 2026 it held $72.8 million in cash and investments and $3.3 million in total debt.
Revenue
$42,000
+162.5% vs year-ago quarter
Net income
$-8.05M
-3.1% vs year-ago quarter
Operating cash flow
$-7.30M
-12.7% vs year-ago quarter
Free cash flow
$-7.43M
-12.8% vs year-ago quarter
EPS
$-0.16
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.29M
Net cash
$69.56M
Q3 FY2026
Operating margin
-38755.2%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- SERA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1534969
- Former names
- SERA PROGNOSTICS, INC. (until Nov 4, 2026)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $42,000 | $30,000 | $14,000 | $10,000 | $16,000 |
| Operating income | -$8.9M | -$10.0M | -$9.4M | -$9.0M | -$9.0M |
| Net income | -$8.1M | -$9.1M | -$8.4M | -$7.9M | -$7.8M |
| Diluted EPS | -$0.16 | -$0.18 | -$0.17 | -$0.16 | -$0.16 |
| Operating cash flow | -$7.3M | -$6.3M | -$8.8M | -$6.1M | -$6.5M |
| Free cash flow | -$7.4M | -$6.3M | -$8.8M | -$6.5M | -$6.6M |
| Total assets | $80.0M | $86.7M | $93.5M | $101.9M | $108.1M |
| Total liabilities | $27.5M | $27.4M | $25.9M | $26.5M | $25.9M |
| Stockholders' equity | $52.4M | $59.4M | $67.6M | $75.4M | $82.2M |
| Cash and investments | $72.8M | $80.3M | $86.8M | $95.8M | $102.4M |
| Total debt | $3.3M | $3.0M | $2.5M | $2.3M | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 19, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 25, 2026 |
All 660 Sera Prognostics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.